Analyst Price Target is $41.43
▲ +1,343.50% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for 89bio in the last 3 months. The average price target is $41.43, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,343.50% upside from the last price of $2.87.
Current Consensus is
The current consensus among 7 investment analysts is to buy stock in 89bio. This Buy consensus rating has held steady for over two years.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.